Jerome-CLAIN

Jerome CLAIN

MEDS
Responsable MEDS, Maître de Conférence des Universités
Paris, Faculté de pharmacie

Publications

Mutation in Plasmodium falciparum BTB/POZ domain of K13 protein confers artemisinin resistance Antimicrob Agents Chemother (2021) Oct 4:AAC0132021
Challenges in the clinical development pathway for triple and multiple drug combinations in the treatment of uncomplicated falciparum malaria Malar J (2022) 2022;21(1):61
Circulation of an Artemisinin-Resistant Malaria Lineage in a Traveler Returning from East Africa to France Clin Infect Dis (2022) 2022;75(7):1242-1244
5WBF: a low-cost and straightforward whole blood filtration method suitable for whole-genome sequencing of P. falciparum clinical isolates Malar J (2022) 2022;21(1):51
Splenic clearance of rigid erythrocytes as an inherited mechanism for splenomegaly and natural resistance to malaria EBioMedicine (2022) 2022;82:104167
Development and Optimization of a Selective Whole-Genome Amplification To Study Plasmodium ovale Spp Microbiol Spectr (2022) 2022 ;10(5):e0072622
Mutation in the Plasmodium falciparum BTB/POZ Domain of K13 Protein Confers Artemisinin Resistance Antimicrob Agents Chemother (2022) 2022;66(1):e0132021
Effect of Drug Pressure on Promoting the Emergence of Antimalarial-Resistant Parasites among Pregnant Women in Ghana Antimicrob Agents Chemother (2020) 64(6):e02029-19
A Chemically Stable Fluorescent Mimic of Dihydroartemisinin, Artemether, and Arteether with Conserved Bioactivity and Specificity Shows High Pharmacological Relevance to the Antimalarial Drugs ACS Infect Dis (2020) 6(7):1532-1547
Artemisinin and its derivatives target mitochondrial c-type cytochromes in yeast and human cells Biochim Biophys Acta Mol Cell Res (2020) 1867(5):118661